U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H22N2O
Molecular Weight 234.3373
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of LIDOCAINE

SMILES

CCN(CC)CC(=O)NC1=C(C)C=CC=C1C

InChI

InChIKey=NNJVILVZKWQKPM-UHFFFAOYSA-N
InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)

HIDE SMILES / InChI
Molecular Formula C14H22N2O
Molecular Weight 234.3373
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Unknown
86413
Substance Class Chemical
Created
by admin
on Fri Dec 15 15:22:36 UTC 2023
Edited
by admin
on Fri Dec 15 15:22:36 UTC 2023
Record UNII
98PI200987
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
LIDOCAINE
EP   GREEN BOOK   HSDB   INCI   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD  
INN   INCI  
Official Name English
LIDOCAINE [HSDB]
Common Name English
lidocaine [INN]
Common Name English
2-(DIETHYLAMINO)-N-(2,6-DIMETHYLPHENYL)ACETAMIDE
Systematic Name English
EMLA COMPONENT LIDOCAINE
Common Name English
ZTLIDO
Brand Name English
LIDOCAINE COMPONENT OF ORAQIX
Common Name English
LANABIOTIC COMPONENT LIDOCAINE
Common Name English
LIDOCAINE [WHO-IP]
Common Name English
LIGNOCAINE
Common Name English
LIDOCAINE COMPONENT OF ROCEPHIN KIT
Common Name English
LIDOCAINE COMPONENT OF EMLA
Common Name English
LIDOCAINE [EP MONOGRAPH]
Common Name English
LIDOCAINE COMPONENT OF SYNERA
Common Name English
XYLESTESIN
Common Name English
2-(DIETHYLAMINO)-2',6'-ACETOXYLIDIDE
Common Name English
FORTACIN COMPONENT LIDOCAINE
Brand Name English
DIETHYLAMINO-2,6-DIMETHYLACETANILIDE
Common Name English
LIDOCAINE [INCI]
Common Name English
LIDOCAINE [USP-RS]
Common Name English
LIDOCAINE [MI]
Common Name English
LIDOCAINE [VANDF]
Common Name English
DENTIPATCH
Brand Name English
LIDOCAINE COMPONENT OF LANABIOTIC
Common Name English
LIDOCAINE [USP MONOGRAPH]
Common Name English
Lidocaine [WHO-DD]
Common Name English
LIDOCAINE [MART.]
Common Name English
ORAQIX COMPONENT LIDOCAINE
Common Name English
LIDOCAINE [ORANGE BOOK]
Common Name English
SYNERA COMPONENT LIDOCAINE
Common Name English
ROCEPHIN KIT COMPONENT LIDOCAINE
Common Name English
ALGRX 3268
Code English
LIDOCAIN COMPONENT OF FORTACINE
Brand Name English
LIDOCAINE [JAN]
Common Name English
LIDOCAINE [GREEN BOOK]
Common Name English
LIDODERM
Brand Name English
XYLOCAINE
Common Name English
NSC-40030
Code English
ALPHACAINE
Brand Name English
ALGRX-3268
Code English
ACETAMIDE, 2-(DIETHYLAMINO)-N-(2,6-DIMETHYLPHENYL)-
Systematic Name English
2-DIETHYLAMINO-2',6'-ACETOXYLIDIDE
Common Name English
SOLARCAINE
Common Name English
LIDOCAINUM [WHO-IP LATIN]
Common Name English
Classification Tree Code System Code
WHO-ESSENTIAL MEDICINES LIST 1.2 (LID/EPI)
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 1.2
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
CFR 21 CFR 348.10
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
CFR 21 CFR 522.810
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
NDF-RT N0000175976
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
NCI_THESAURUS C245
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC C01BB01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC N01BB02
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC C05AD01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QD04AB01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
CFR 21 CFR 862.3555
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QC01BB01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC N01BB52
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QS02DA01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
CFR 21 CFR 346.10
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
NDF-RT N0000007681
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
FDA ORPHAN DRUG 92395
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC D04AB01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC S01HA07
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QN01BB02
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QD04AB51
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QS01HA07
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC R02AD02
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
NDF-RT N0000175426
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
CFR 21 CFR 522.1662B
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QN01BB52
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
NDF-RT N0000175682
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
NCI_THESAURUS C93038
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ESSENTIAL MEDICINES LIST 12.2
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
EMA ASSESSMENT REPORTS FORTACIN (AUTHORIZED: SEXUAL DYSFUNCTION, PHYSIOLOGICAL)
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-ATC S02DA01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QC05AD01
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
WHO-VATC QR02AD02
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
Code System Code Type Description
HSDB
3350
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
ECHA (EC/EINECS)
205-302-8
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
EPA CompTox
DTXSID1045166
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
NCI_THESAURUS
C614
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
MERCK INDEX
m6805
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY Merck Index
PUBCHEM
3676
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
INN
4202
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
RXCUI
6387
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY RxNorm
WHO INTERNATIONAL PHARMACOPEIA
LIDOCAINE
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY Description: A white or slightly yellow, crystalline powder; odour, characteristic. Solubility: Practically insoluble in water; very soluble in ethanol (~750 g/l) TS; freely soluble in benzene R and ether R. Category: Local anaesthetic. Storage: Lidocaine should be kept in a tightly closed container, protected from light. Additional information: Lidocaine causes local numbness after being placed on the tongue. Definition: Lidocaine contains not less than 99.0% and not more than 101.0% of C14H22N2O, calculated with reference to the dried substance.
DRUG CENTRAL
1579
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
DRUG BANK
DB00281
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
CAS
91484-71-8
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
SUPERSEDED
SMS_ID
100000091713
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
ChEMBL
CHEMBL79
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
IUPHAR
2623
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
FDA UNII
98PI200987
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
LACTMED
Lidocaine
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
NSC
40030
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
RS_ITEM_NUM
1366002
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
DAILYMED
98PI200987
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
EVMPD
SUB08507MIG
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
MESH
D008012
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
WIKIPEDIA
LIDOCAINE
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
CHEBI
6456
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
CAS
137-58-6
Created by admin on Fri Dec 15 15:22:36 UTC 2023 , Edited by admin on Fri Dec 15 15:22:36 UTC 2023
PRIMARY
Related Record Type Details
CYTOCHROME P450 2E1
METABOLIC ENZYME -> SUBSTRATE
PLASMA PROTEIN FRACTION (HUMAN)
BINDER->LIGAND
LIVER CARBOXYLESTERASE 1
METABOLIC ENZYME -> SUBSTRATE
Structure of LIDOCAINE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
Structure of LIDOCAINE
BASIS OF STRENGTH->SUBSTANCE
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LIDOCAINE HYDROCHLORIDE ANHYDROUS
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE TOSYLATE
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE BICARBONATE
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE IMINODIACETIC ACID
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE MALEATE
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE CARBONATE
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE HYDROCHLORIDE
SALT/SOLVATE -> PARENT
Structure of LIDOCAINE SULFATE
SALT/SOLVATE -> PARENT
Related Record Type Details
Structure of NORLIDOCAINE
METABOLITE ACTIVE -> PARENT
MAJOR
PLASMA
Structure of 2,6-DIMETHYLPHENYLHYDROXYLAMINE
METABOLITE -> PARENT
Structure of GLYCINEXYLIDIDE
METABOLITE LESS ACTIVE -> PARENT
PLASMA
Structure of 2,6-XYLIDINE
METABOLITE INACTIVE -> PARENT
has unknown pharmacologic activity but is carcinogenic in rats (http://srsid.fda.gov:9618/ePS/SubstanceRelationship.do?substanceMode=update&calledFrom=viewUpdateIngredient&RELATIONSHIP_ID=128538&SUBSTANCE_ID=1422&BDNUM=0021807AA).
PLASMA
Structure of ACETYLHYDRAZINE
METABOLITE TOXIC -> PARENT
Adversely affected mental performance and caused headaches in man.
Structure of NORLIDOCAINE
METABOLITE LESS ACTIVE -> PARENT
Structure of 2,6-DIMETHYLACETAMINOPHEN
METABOLITE -> PARENT
MAJOR
URINE
Structure of 4-AMINO-3,5-DIMETHYLPHENOL
METABOLITE INACTIVE -> PARENT
major excreted metabolite.
MAJOR
URINE
Related Record Type Details
Structure of 2-(ISOPROPYLAMINO)-2',6'-ACETOXYLIDIDE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of N-ACETYL-2,6-XYLIDINE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,2'-IMINOBIS(N-(2,6-DIMETHYLPHENYL)ACETAMIDE)
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-DIETHYLAMINO-2',5'-ACETOXYLIDIDE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-DIETHYLAMINO-2',3'-ACETOXYLIDIDE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,6-XYLIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-(DIETHYLAMINO)-2',4'-ACETOXYLIDIDE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2,6-XYLIDINE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of LIDOCAINE N2-OXIDE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-CHLORO-2',6'-ACETOXYLIDIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Structure of 2-CHLORO-2',6'-ACETOXYLIDIDE
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
USP
Structure of NORLIDOCAINE
IMPURITY -> PARENT
UNSPECIFIED
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
Structure of LIDOCAINE
ACTIVE MOIETY
Name Property Type Amount Referenced Substance Defining Parameters References
Volume of Distribution PHARMACOKINETIC Crosses blood-brain barrier

NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966